Back to search

Peptide record

TPDB27193

Antibacterial Anticancer Antifungal Toxicity modified_plain modified
4 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB27193
Antibacterial Anticancer Antifungal Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
Peptipedia CAFPdb dbAMP
modified_plain
Yes
A 4-aa modified multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from Peptipedia, CAFPdb, and dbAMP, with an available 3D structural model.
Modified, details unspecified
Sequence
XXXX
Physicochemical Analysis
ARNDCEQGHILKMFPSTWYV
18.02
6.02
0
0
0
-0
0.00
0.000
0.00
Mammalian: Yeast: E.coli:
0
0.00
0
Residue Composition
number
0
A
0
R
0
N
0
D
0
C
0
E
0
Q
0
G
0
H
0
I
0
L
0
K
0
M
0
F
0
P
0
S
0
T
0
W
0
Y
0
V
Amino Acid Distribution
A: 0 R: 0 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 0 H: 0 I: 0 L: 0 K: 0 M: 0 F: 0 P: 0 S: 0 T: 0 W: 0 Y: 0 V: 0
Chemical Descriptors
4
18.02
6.02
-0
0.00
0.000
Evidence Records 18 records
Evidence 1 Activity

Activity

EC50
Toxicity
0.0427 µM
Cytotoxic
EC50 | 0.0427 | µM | target cell: Mouse lymphocytes

Target

Mouse lymphocytes

Source & Reference

NA
DBAASP
Microcolins A and B, new immunosuppressive peptides from the blue-green alga Lyngbya majuscula. | J Nat Prod | 1992
Evidence 2 Activity

Activity

50% Cytotoxicity
Toxicity
0.191 µM
Cytotoxic
50% Cytotoxicity | 0.191 | µM | target cell: Mouse lymphocytes

Target

Mouse lymphocytes

Source & Reference

NA
DBAASP
Microcolins A and B, new immunosuppressive peptides from the blue-green alga Lyngbya majuscula. | J Nat Prod | 1992
Evidence 3 Activity

Activity

50% Hemolysis
Toxicity
>1000 µg/mL
Hemolytic Cytotoxic
50% Hemolysis | >1000 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Development of novel membrane active lipidated peptidomimetics active against drug resistant clinical isolates. | Bioorg Med Chem | 2014
Evidence 4 Activity

Activity

50% Hemolysis
Toxicity
900 µg/mL
Hemolytic Cytotoxic
50% Hemolysis | 900 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Development of novel membrane active lipidated peptidomimetics active against drug resistant clinical isolates. | Bioorg Med Chem | 2014
Evidence 5 Activity

Activity

50% Hemolysis
Toxicity
750 µg/mL
Hemolytic Cytotoxic
50% Hemolysis | 750 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Development of novel membrane active lipidated peptidomimetics active against drug resistant clinical isolates. | Bioorg Med Chem | 2014
Evidence 6 Activity

Activity

50% Hemolysis
Toxicity
450 µg/mL
Hemolytic Cytotoxic
50% Hemolysis | 450 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Development of novel membrane active lipidated peptidomimetics active against drug resistant clinical isolates. | Bioorg Med Chem | 2014
Evidence 7 Activity

Activity

50% Hemolysis
Toxicity
250 µg/mL
Hemolytic Cytotoxic
50% Hemolysis | 250 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Development of novel membrane active lipidated peptidomimetics active against drug resistant clinical isolates. | Bioorg Med Chem | 2014
Evidence 8 Activity

Activity

50% Cytotoxicity
Toxicity
12.5 µM
Cytotoxic
50% Cytotoxicity | 12.5 | µM | target cell: Human embryonic kidney HEK293T cells

Target

Human embryonic kidney HEK293T cells

Source & Reference

NA
DBAASP
Novel tetrameric cell penetrating antimicrobial peptoids effective against mycobacteria and drug-resistant Staphylococcus aureus | Front Biosci (Landmark Ed) | 2022
Evidence 9 Activity

Activity

50% Cytotoxicity
Toxicity
>100 µM
Cytotoxic
50% Cytotoxicity | >100 | µM | target cell: Human embryonic kidney HEK293T cells

Target

Human embryonic kidney HEK293T cells

Source & Reference

NA
DBAASP
Novel tetrameric cell penetrating antimicrobial peptoids effective against mycobacteria and drug-resistant Staphylococcus aureus | Front Biosci (Landmark Ed) | 2022
Evidence 10 Activity

Activity

50% Cytotoxicity
Toxicity
25 µM
Cytotoxic
50% Cytotoxicity | 25 | µM | target cell: Human embryonic kidney HEK293T cells

Target

Human embryonic kidney HEK293T cells

Source & Reference

NA
DBAASP
Novel tetrameric cell penetrating antimicrobial peptoids effective against mycobacteria and drug-resistant Staphylococcus aureus | Front Biosci (Landmark Ed) | 2022
Evidence 11 Activity

Activity

50% Cytotoxicity
Toxicity
50 µM
Cytotoxic
50% Cytotoxicity | 50 | µM | target cell: Human embryonic kidney HEK293T cells

Target

Human embryonic kidney HEK293T cells

Source & Reference

NA
DBAASP
Novel tetrameric cell penetrating antimicrobial peptoids effective against mycobacteria and drug-resistant Staphylococcus aureus | Front Biosci (Landmark Ed) | 2022
Evidence 12 Activity

Activity

10% Hemolysis
Toxicity
>200 µg/mL
Hemolytic Cytotoxic
10% Hemolysis | >200 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Evaluation of peptoid mimics of short, lipophilic peptide antimicrobials. | Int J Antimicrob Agents | 2020
Evidence 13 Activity

Activity

10% Hemolysis
Toxicity
127.6±2.4 µg/mL
Hemolytic Cytotoxic
10% Hemolysis | 127.6±2.4 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Evaluation of peptoid mimics of short, lipophilic peptide antimicrobials. | Int J Antimicrob Agents | 2020
Evidence 14 Activity

Activity

10% Hemolysis
Toxicity
27.5±1.1 µg/mL
Hemolytic Cytotoxic
10% Hemolysis | 27.5±1.1 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Evaluation of peptoid mimics of short, lipophilic peptide antimicrobials. | Int J Antimicrob Agents | 2020
Evidence 15 Activity

Activity

100% Hemolysis
Toxicity
50 µM
Hemolytic Cytotoxic
100% Hemolysis | 50 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Novel lysine-peptoid hybrids with antibacterial properties | J Pept Sci | 2005
Evidence 16 Activity

Activity

50% Hemolysis
Toxicity
>1000 µg/mL
Hemolytic Cytotoxic
50% Hemolysis | >1000 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Systematic study of non-natural short cationic lipopeptides as novel broad-spectrum antimicrobial agents. | Chem Biol Drug Des | 2013
Evidence 17 Activity

Activity

50% Hemolysis
Toxicity
500 µg/mL
Hemolytic Cytotoxic
50% Hemolysis | 500 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Systematic study of non-natural short cationic lipopeptides as novel broad-spectrum antimicrobial agents. | Chem Biol Drug Des | 2013
Evidence 18 Activity

Activity

50% Hemolysis
Toxicity
250 µg/mL
Hemolytic Cytotoxic
50% Hemolysis | 250 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Systematic study of non-natural short cationic lipopeptides as novel broad-spectrum antimicrobial agents. | Chem Biol Drug Des | 2013